Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV is positioned favorably with its late-stage development of deucrictibant, a novel oral bradykinin B2 receptor antagonist targeting hereditary angioedema (HAE), due to substantial potential for total revenue growth exceeding consensus estimates. The promising Phase 2 data indicate profound and durable quality-of-life improvements for patients, with 100% of participants achieving "well-controlled HAE" status, and a potential market share capture stemming from the lack of approved therapies. Additionally, the impressive clinical efficacy demonstrated by a 98% reduction in monthly attacks and robust single-dose durability suggests that deucrictibant could emerge as a best-in-class oral rescue therapy in the HAE market.

Pharvaris NV faces challenges that contribute to a negative outlook on its stock, primarily due to anticipated changes in the market landscape, including the introduction of new gene therapies, which could reduce the addressable patient population significantly. The company’s sales and cash flow estimates are at risk if reimbursement for approved compounds fails to meet initial modeling assumptions, potentially hindering financial performance. Furthermore, concerns about inadequate funding to support development efforts could critically impact Pharvaris’s ability to advance its pipeline and effectively execute ongoing pivotal studies of deucrictibant.